Market Overview

Morgan Stanley Sees Possible Good Things Ahead For Medtronic

Related MDT
Benzinga's M&A Chatter for Tuesday August 26, 2014
S&P 500 Closes Above 2,000; Dow Hits New All-Time High As Markets Continue To Rally
IRS, Eh? Tim Hortons Deal Could Lower Burger King's Tax Bill (Fox Business)

In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Medtronic (NYSE: MDT).

In the report, Morgan Stanley noted, “Reveal Linq may the sleeper product of HRS 2014. First generation Reveal was a tertiary product worth only ~$50-60 million in sales, but the second gen device is different. Reveal Linq makes major strides in innovation and telemetry and comes at a 20% price premium. With unusually strong clinical feedback, this device could open up a renewed global market for cardiac monitoring worth $500 million or more.”

Medtronic closed on Thursday at $59.43.

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (MDT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters